Assess the risk of stroke and bleeding in your non-valvular AF patients

Assess the Risk of Stroke and Bleeding in your
Non-valvular AF Patients

DOWNLOAD THE APP

The ESC guidelines recommend to assess the risks of stroke and bleeding in the decision-making process for thromboprophylaxis in patients with non-valvular AF by using the CHA2DS2-VASc and HAS-BLED scores, respectively.

Stroke Risk Assessment

CHA2DS2-VASc is a risk assessment system developed by Lip et al., which refines the older CHADS2 score by including additional stroke risk factors and putting greater emphasis on age as a risk factor.1,2

Bleeding Risk Assessment

HAS-BLED was developed as a practical risk score to estimate the 1-year risk for major bleeding in patients with AF taking warfarin.3

Assess the risk of stroke & bleeding of your non-valvular AF patients with the stroke-bleed risk calculator

The Boston Scientific Stroke-Bleed Risks Calculator will help you easily balance the risk of stroke against the risk of bleeding prior to deciding the best treatment option for your AF patients; consider LAAC therapy for your AF patients who are at high risk of stroke and bleeding.

Download the App now!

Calculate the stroke and bleeding risk fro your laptop

CHA₂DS₂-VASc Score Calculator

Assess the stroke risk in your NVAF patients

HAS-BLED Calculator

Assess the bleeding risk in your NVAF patients

Innovative One-Time Solution

Review the clinical data that reinforces why WATCHMAN is a proven option to reduce the risk of stroke for patients with non-valvular AF.

Clinical Results

References
1. Lip GY et al. Chest 2010;137(2):263-72.
2. Camm AJ et al. Eur Heart J 2010;31:2369-2429.
3. Pisters, R et al. Chest 2010 Nov;138(5):1093-100.

CAUTION: The law restricts these devices to sale by our on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device.
Information for the use only in countries with applicable health authority product registrations. Information contained herein is for distribution outside the U.S., Japan and France.